Arbutus Biopharma Corporation

Xenon Pharmaceuticals Inc.

Protiva Biotherapeutics, Inc.

Mark Wood

James Heyes

Alan Martin

Richard James Holland

Shaoyi Sun

Sultan Chowdhury

Serguei Sviridov

Jianmin Fu

Shifeng Liu

Mikhail A Chafeev

Alla Yurevna Zenova

Jianyu Sun

Jonathan David Langille

Lauren Fraser

Qi Jia

Nagasree Chakka

Simon James Gauthier

Jean-Jacques Alexandre Cadieux

Tom Hsieh

Amy Frances Douglas

Zoran Cikojevic

Amy C H Lee

Bruce D Dorsey

Yingzhi Bi

Adam Judge

Dimitar B Gotchev

Kieu Lam

Duyan Nguyen

Shuai Chen

Emily P Thi

Ian MacLachlan

Michael J Abrams

Lorne Ralph Palmer

Ramesh Kakarla

Nicholas Michael Snead

Laurèn Danielle Bailey

Edward D Yaworski

Marjorie Ann Robbins

Stephen P Reid

Xin Ye

Ian Maclachlan

Kieu Mong Lam

Alan D Martin

The invention provides PEG-conjugated lipids of formula (I): A-B-C (I) wherein A, B, and C have any of the values defined in the specification, as well as compositions comprising the PEG-conjugated lipids of formula (I), nucleic acid lipid nanoparticles comprising the PEG-conjugated lipids of formula (I), and methods of using the PEG-conjugated lipids of formula (I), the compositions, and the nucleic acid nanoparticles.

Negatively charged peg-lipid conjugates

Certain embodiments of the invention provide a cationic lipid of formula (I): wherein R, R, Rand Rare defined as described herein, as well as methods of making these lipids. Certain embodiments of the invention also provide nucleic acid-lipid particles comprising a cationic lipid of formula (I), methods of making the lipid particles, and methods of delivering and/or administering the lipid particles.

Cationic lipids containing silicon

The invention provides certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic double stranded siRNA to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).

Targeted compositions

The invention provides conjugates that comprise a targeting moiety, a nucleic acid, and optional linking groups as well as synthetic intermediates and synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic nucleic acids to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).

Targeted nucleic acid conjugate compositions

The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel, trialkyl, cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses.

Trialkyl cationic lipids and methods of use thereof

The present invention includes substituted pyridinone-containing tricyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infection in a patient. In certain embodiments, the compounds and compositions of the invention inhibit and/or reduce HBsAg secretion.

Substituted pyridinone-containing trycyclic compounds, and methods using same

The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.

Cyclic cationic lipids and methods of use

This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

Spiro-oxindole compounds and their use as therapeutic agents

Cationic lipids and methods of use thereof

The present invention provides compositions and methods for the delivery of interfering RNAs such as siRNAs that silence APOB expression in cells such as liver cells. In particular, the nucleic acid-lipid particles provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells such as liver cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of APOB at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.

Compositions and methods for silencing apolipoprotein B

Growing community of inventors

Port Moody, Canada

Mark Wood